The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders

Neuron

Volumn 86, Issue 5, 2015, Pages 1119-1130

  Braat, Sien ^a   Kooy, R Frank ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 4 AMINOBUTYRIC ACID A RECEPTOR BETA3; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA3; BENZODIAZEPINE RECEPTOR AFFECTING AGENT;

AUTISM; CHROMATIN ASSEMBLY AND DISASSEMBLY; DEVELOPMENTAL DISORDER; EPILEPSY; FRAGILE X SYNDROME; GABAERGIC SYSTEM; GENE DOSAGE; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HIPPOCAMPAL CA3 REGION; HUMAN; INHIBITORY POSTSYNAPTIC POTENTIAL; INTELLECTUAL IMPAIRMENT; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RETT SYNDROME; REVIEW; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SOMATOSENSORY CORTEX; ANIMAL; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DEVELOPMENTAL DISABILITIES; DRUG DELIVERY SYSTEM; GENETICS; METABOLISM; NERVOUS SYSTEM DISEASES; TRENDS;

ANIMALS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DEVELOPMENTAL DISABILITIES; DRUG DELIVERY SYSTEMS; FRAGILE X SYNDROME; GABA MODULATORS; HUMANS; NERVOUS SYSTEM DISEASES; RECEPTORS, GABA-A; RETT SYNDROME;

EID: 84930531864     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2015.03.042     Document Type: Review

References (142)

1. Abdala A.P., Dutschmann M., Bissonnette J.M., Paton J.F. Correction of respiratory disorders in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. USA 2010, 107:18208-18213.
2. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23:185-188.
3. Ascano M., Mukherjee N., Bandaru P., Miller J.B., Nusbaum J.D., Corcoran D.L., Langlois C., Munschauer M., Dewell S., Hafner M., et al. FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 2012, 492:382-386.
4. Atack J.R. GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer. CNS Neurosci. Ther. 2008, 14:25-35.
5. Baird G., Simonoff E., Pickles A., Chandler S., Loucas T., Meldrum D., Charman T. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 2006, 368:210-215.
6. Ballard T.M., Knoflach F., Prinssen E., Borroni E., Vivian J.A., Basile J., Gasser R., Moreau J.L., Wettstein J.G., Buettelmann B., et al. RO4938581, a novel cognitive enhancer acting at GABA(A) alpha5 subunit-containing receptors. Psychopharmacology (Berl). 2009, 202:207-223.
7. A) receptor dysfunction in epilepsy: a mutation in the γ2-subunit gene. Nat. Genet. 2001, 28:46-48.
8. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27:370-377.
9. Belelli D., Harrison N.L., Maguire J., Macdonald R.L., Walker M.C., Cope D.W. Extrasynaptic GABAA receptors: form, pharmacology, and function. J. Neurosci. 2009, 29:12757-12763.
10. Ben-Ari Y. Excitatory actions of gaba during development: the nature of the nurture. Nat. Rev. Neurosci. 2002, 3:728-739.
11. Berry-Kravis E.M., Hessl D., Rathmell B., Zarevics P., Cherubini M., Walton-Bowen K., Mu Y., Nguyen D.V., Gonzalez-Heydrich J., Wang P.P., et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci. Transl. Med. 2012, 4:152ra127.
12. Blue M.E., Naidu S., Johnston M.V. Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome. Exp. Neurol. 1999, 156:345-352.
13. Bowery N.G., Bettler B., Froestl W., Gallagher J.P., Marshall F., Raiteri M., Bonner T.I., Enna S.J. International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function. Pharmacol. Rev. 2002, 54:247-264.
14. Braat S., Kooy R.F. Fragile X syndrome neurobiology translates into rational therapy. Drug Discov. Today 2014, 19:510-519.
15. Braat S., Kooy R.F. Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials. Neuropharmacology 2015, 88:48-54.
16. A receptor is an FMRP target with therapeutic potential in fragile X syndrome. Cell Cycle 2015, 0. Published online March 19, 2015. 10.4161/15384101.2014.989114.
17. Calfa G., Percy A.K., Pozzo-Miller L. Experimental models of Rett syndrome based on Mecp2 dysfunction. Exp. Biol. Med. (Maywood) 2011, 236:3-19.
18. Carter R.B., Wood P.L., Wieland S., Hawkinson J.E., Belelli D., Lambert J.J., White H.S., Wolf H.H., Mirsadeghi S., Tahir S.H., et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J. Pharmacol. Exp. Ther. 1997, 280:1284-1295.
19. Carver C.M., Reddy D.S. Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. Psychopharmacology (Berl.) 2013, 230:151-188.
20. Carvill G.L., Weckhuysen S., McMahon J.M., Hartmann C., Møller R.S., Hjalgrim H., Cook J., Geraghty E., O'Roak B.J., Petrou S., et al. GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. Neurology 2014, 82:1245-1253.
21. Castrén E., Elgersma Y., Maffei L., Hagerman R. Treatment of neurodevelopmental disorders in adulthood. J. Neurosci. 2012, 32:14074-14079.
22. Cea-Del Rio C.A., Huntsman M.M. The contribution of inhibitory interneurons to circuit dysfunction in fragile X syndrome. Front. Cell. Neurosci. 2014, 8:245.
23. Chahrour M., Zoghbi H.Y. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007, 56:422-437.
24. Chang S., Bray S.M., Li Z., Zarnescu D.C., He C., Jin P., Warren S.T. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat. Chem. Biol. 2008, 4:256-263.
25. Chao H.T., Chen H., Samaco R.C., Xue M., Chahrour M., Yoo J., Neul J.L., Gong S., Lu H.C., Heintz N., et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 2010, 468:263-269.
26. Cheah C.S., Yu F.H., Westenbroek R.E., Kalume F.K., Oakley J.C., Potter G.B., Rubenstein J.L., Catterall W.A. Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. Proc. Natl. Acad. Sci. USA 2012, 109:14646-14651.
27. Chen R.Z., Akbarian S., Tudor M., Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 2001, 27:327-331.
28. Chen C.H., Huang C.C., Cheng M.C., Chiu Y.N., Tsai W.C., Wu Y.Y., Liu S.K., Gau S.S. Genetic analysis of GABRB3 as a candidate gene of autism spectrum disorders. Mol. Autism 2014, 5:36.
29. Chiron C., Marchand M.C., Tran A., Rey E., d'Athis P., Vincent J., Dulac O., Pons G. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000, 356:1638-1642.
30. Claes L., Del-Favero J., Ceulemans B., Lagae L., Van Broeckhoven C., De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am. J. Hum. Genet. 2001, 68:1327-1332.
31. Claes L.R., Deprez L., Suls A., Baets J., Smets K., Van Dyck T., Deconinck T., Jordanova A., De Jonghe P. The SCN1A variant database: a novel research and diagnostic tool. Hum. Mutat. 2009, 30:E904-E920.
32. Coe B.P., Witherspoon K., Rosenfeld J.A., van Bon B.W., Vulto-van Silfhout A.T., Bosco P., Friend K.L., Baker C., Buono S., Vissers L.E., et al. Refining analyses of copy number variation identifies specific genes associated with developmental delay. Nat. Genet. 2014, 46:1063-1071.
33. Cossette P., Liu L., Brisebois K., Dong H., Lortie A., Vanasse M., Saint-Hilaire J.M., Carmant L., Verner A., Lu W.Y., et al. Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat. Genet. 2002, 31:184-189.
34. Crabbe J.C., Wahlsten D., Dudek B.C. Genetics of mouse behavior: interactions with laboratory environment. Science 1999, 284:1670-1672.
35. Cui Y., Costa R.M., Murphy G.G., Elgersma Y., Zhu Y., Gutmann D.H., Parada L.F., Mody I., Silva A.J. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 2008, 135:549-560.
36. D'Hulst C., Kooy R.F. The GABAA receptor: a novel target for treatment of fragile X?. Trends Neurosci. 2007, 30:425-431.
37. D'Hulst C., Atack J.R., Kooy R.F. The complexity of the GABAA receptor shapes unique pharmacological profiles. Drug Discov. Today 2009, 14:866-875.
38. Darnell J.C., Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. Nat. Neurosci. 2013, 16:1530-1536.
39. Darnell J.C., Van Driesche S.J., Zhang C., Hung K.Y., Mele A., Fraser C.E., Stone E.F., Chen C., Fak J.J., Chi S.W., et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146:247-261.
40. A receptors enhances cognition. J. Pharmacol. Exp. Ther. 2006, 316:1335-1345.
41. De Rubeis S., He X., Goldberg A.P., Poultney C.S., Samocha K., Cicek A.E., Kou Y., Liu L., Fromer M., Walker S., et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014, 515:209-215. DDD Study, Homozygosity Mapping Collaborative for AutismHomozygosity Mapping Collaborative for Autism, UK10K ConsortiumUK10K Consortium.
42. A receptors is a susceptibility locus for generalized epilepsies. Hum. Mol. Genet. 2004, 13:1315-1319.
43. Dikow N., Maas B., Karch S., Granzow M., Janssen J.W., Jauch A., Hinderhofer K., Sutter C., Schubert-Bast S., Anderlid B.M., et al. 3p25.3 microdeletion of GABA transporters SLC6A1 and SLC6A11 results in intellectual disability, epilepsy and stereotypic behavior. Am. J. Med. Genet. A. 2014, 164A:3061-3068.
44. Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011, 52(Suppl 2):3-9.
45. Duarte S.T., Armstrong J., Roche A., Ortez C., Pérez A., O'Callaghan Mdel.M., Pereira A., Sanmartí F., Ormazábal A., Artuch R., et al. Abnormal expression of cerebrospinal fluid cation chloride cotransporters in patients with Rett syndrome. PLoS ONE 2013, 8:e68851.
46. Dutton S.B., Makinson C.D., Papale L.A., Shankar A., Balakrishnan B., Nakazawa K., Escayg A. Preferential inactivation of Scn1a in parvalbumin interneurons increases seizure susceptibility. Neurobiol. Dis. 2013, 49:211-220.
47. El-Khoury R., Panayotis N., Matagne V., Ghata A., Villard L., Roux J.C. GABA and glutamate pathways are spatially and developmentally affected in the brain of Mecp2-deficient mice. PLoS ONE 2014, 9:e92169.
48. De novo mutations in the classic epileptic encephalopathies. Nature 2013, 501:217-221. Epi4K Consortium, Epilepsy Phenome/Genome ProjectEpilepsy Phenome/Genome Project.
49. Erlander M.G., Tillakaratne N.J., Feldblum S., Patel N., Tobin A.J. Two genes encode distinct glutamate decarboxylases. Neuron 1991, 7:91-100.
50. Farrant M., Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci. 2005, 6:215-229.
51. Fatemi S.H., Folsom T.D. GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism. Schizophr. Res. 2014, Published online November 25, 2015. 10.1016/j.schres.2014.10.010.
52. Fatemi S.H., Reutiman T.J., Folsom T.D., Rustan O.G., Rooney R.J., Thuras P.D. Downregulation of GABAA receptor protein subunits α6, β2, δ, ε, γ2, θ, and ρ2 in superior frontal cortex of subjects with autism. J. Autism Dev. Disord. 2014, 44:1833-1845.
53. Fisher J.L. The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology 2009, 56:190-197.
54. Gasnier B. The SLC32 transporter, a key protein for the synaptic release of inhibitory amino acids. Pflugers Arch. 2004, 447:756-759.
55. Gassmann M., Bettler B. Regulation of neuronal GABA(B) receptor functions by subunit composition. Nat. Rev. Neurosci. 2012, 13:380-394.
56. Gilissen C., Hehir-Kwa J.Y., Thung D.T., van de Vorst M., van Bon B.W., Willemsen M.H., Kwint M., Janssen I.M., Hoischen A., Schenck A., et al. Genome sequencing identifies major causes of severe intellectual disability. Nature 2014, 511:344-347.
57. Gilman S.R., Iossifov I., Levy D., Ronemus M., Wigler M., Vitkup D. Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron 2011, 70:898-907.
58. Glykys J., Mody I. Activation of GABAA receptors: views from outside the synaptic cleft. Neuron 2007, 56:763-770.
59. Green E.D., Guyer M.S. Charting a course for genomic medicine from base pairs to bedside. Nature 2011, 470:204-213. National Human Genome Research Institute.
60. Grosenbaugh D.K., Mott D.D. Stiripentol is anticonvulsant by potentiating GABAergic transmission in a model of benzodiazepine-refractory status epilepticus. Neuropharmacology 2013, 67:136-143.
61. Guy J., Hendrich B., Holmes M., Martin J.E., Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 2001, 27:322-326.
62. Hagerman R.J. Physical and behavioral phenotype. Fragile X Syndrome: Diagnosis, Treatment and Research 2002, 3-109. Johns Hopkins University Press, Baltimore, MD. R.J. Hagerman, P.J. Hagerman (Eds.).
63. Hallett M. Tourette syndrome: update. Brain Dev. Published online January 17, 2015 2015, 10.1016/j.braindev.2014.11.005.
64. Hamdan F.F., Srour M., Capo-Chichi J.M., Daoud H., Nassif C., Patry L., Massicotte C., Ambalavanan A., Spiegelman D., Diallo O., et al. De novo mutations in moderate or severe intellectual disability. PLoS Genet. 2014, 10:e1004772.
65. Han S., Tai C., Westenbroek R.E., Yu F.H., Cheah C.S., Potter G.B., Rubenstein J.L., Scheuer T., de la Iglesia H.O., Catterall W.A. Autistic-like behaviour in Scn1a+/- mice and rescue by enhanced GABA-mediated neurotransmission. Nature 2012, 489:385-390.
66. Harris S.W., Hessl D., Goodlin-Jones B., Ferranti J., Bacalman S., Barbato I., Tassone F., Hagerman P.J., Herman H., Hagerman R.J. Autism profiles of males with fragile X syndrome. Am. J. Ment. Retard. 2008, 113:427-438.
67. He Q., Nomura T., Xu J., Contractor A. The developmental switch in GABA polarity is delayed in fragile X mice. J. Neurosci. 2014, 34:446-450.
68. Henderson C., Wijetunge L., Kinoshita M.N., Shumway M., Hammond R.S., Postma F.R., Brynczka C., Rush R., Thomas A., Paylor R., Warren S.T., Vanderklish P.W., Kind P.C., Carpenter R.L., Bear M.F., Healy A.M. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABA(B) receptors with arbaclofen. Sci. Transl. Med. 2012, 4:152ra128.
69. Heulens I., D'Hulst C., Van Dam D., De Deyn P.P., Kooy R.F. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav. Brain Res. 2012, 229:244-249.
70. Hodges L.M., Fyer A.J., Weissman M.M., Logue M.W., Haghighi F., Evgrafov O., Rotondo A., Knowles J.A., Hamilton S.P. Evidence for linkage and association of GABRB3 and GABRA5 to panic disorder. Neuropsychopharmacology 2014, 39:2423-2431.
71. + GABAergic interneurons: from cellular design to microcircuit function. Science 2014, 345:1255263.
72. Iossifov I., O'Roak B.J., Sanders S.J., Ronemus M., Krumm N., Levy D., Stessman H.A., Witherspoon K.T., Vives L., Patterson K.E., et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 2014, 515:216-221.
73. Jin X., Cui N., Zhong W., Jin X.T., Jiang C. GABAergic synaptic inputs of locus coeruleus neurons in wild-type and Mecp2-null mice. Am. J. Physiol. Cell Physiol. 2013, 304:C844-C857.
74. Kalume F., Yu F.H., Westenbroek R.E., Scheuer T., Catterall W.A. Reduced sodium current in Purkinje neurons from Nav1.1 mutant mice: implications for ataxia in severe myoclonic epilepsy in infancy. J. Neurosci. 2007, 27:11065-11074.
75. Katz D.M., Berger-Sweeney J.E., Eubanks J.H., Justice M.J., Neul J.L., Pozzo-Miller L., Blue M.E., Christian D., Crawley J.N., Giustetto M., et al. Preclinical research in Rett syndrome: setting the foundation for translational success. Dis. Model. Mech. 2012, 5:733-745.
76. Kaufmann W.E., Cortell R., Kau A.S.M., Bukelis I., Tierney E., Gray R.M., Cox C., Capone G.T., Stanard P. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am. J. Med. Genet. A. 2004, 129A:225-234.
77. Kerrigan J.F., Shields W.D., Nelson T.Y., Bluestone D.L., Dodson W.E., Bourgeois B.F., Pellock J.M., Morton L.D., Monaghan E.P. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res. 2000, 42:133-139.
78. Krumm N., O'Roak B.J., Shendure J., Eichler E.E. A de novo convergence of autism genetics and molecular neuroscience. Trends Neurosci. 2014, 37:95-105.
79. Laxer K., Blum D., Abou-Khalil B.W., Morrell M.J., Lee D.A., Data J.L., Monaghan E.P. Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Epilepsia 2000, 41:1187-1194. Ganaxolone Presurgical Study Group.
80. Lemonnier E., Degrez C., Phelep M., Tyzio R., Josse F., Grandgeorge M., Hadjikhani N., Ben-Ari Y. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl. Psychiatr. 2012, 2:e202.
81. Lewis P., Abbeduto L., Murphy M., Richmond E., Giles N., Bruno L., Schroeder S. Cognitive, language and social-cognitive skills of individuals with fragile X syndrome with and without autism. J. Intellect. Disabil. Res. 2006, 50:532-545.
82. Li B.M., Liu X.R., Yi Y.H., Deng Y.H., Su T., Zou X., Liao W.P. Autism in Dravet syndrome: prevalence, features, and relationship to the clinical characteristics of epilepsy and mental retardation. Epilepsy Behav. 2011, 21:291-295.
83. Li D., Sulovari A., Cheng C., Zhao H., Kranzler H.R., Gelernter J. Association of gamma-aminobutyric acid A receptor α2 gene (GABRA2) with alcohol use disorder. Neuropsychopharmacology 2014, 39:907-918.
84. Lossin C. A catalog of SCN1A variants. Brain Dev. 2009, 31:114-130.
85. 11C]flumazenil. Neuroimage 2004, 22:22-28.
86. Lynex C.N., Carr I.M., Leek J.P., Achuthan R., Mitchell S., Maher E.R., Woods C.G., Bonthon D.T., Markham A.F. Homozygosity for a missense mutation in the 67 kDa isoform of glutamate decarboxylase in a family with autosomal recessive spastic cerebral palsy: parallels with Stiff-Person Syndrome and other movement disorders. BMC Neurol. 2004, 4:20.
87. Ma D.Q., Whitehead P.L., Menold M.M., Martin E.R., Ashley-Koch A.E., Mei H., Ritchie M.D., Delong G.R., Abramson R.K., Wright H.H., et al. Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. Am. J. Hum. Genet. 2005, 77:377-388.
88. Madsen K.K., White H.S., Schousboe A. Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol. Ther. 2010, 125:394-401.
89. Maljevic S., Krampfl K., Cobilanschi J., Tilgen N., Beyer S., Weber Y.G., Schlesinger F., Ursu D., Melzer W., Cossette P., et al. A mutation in the GABA(A) receptor alpha(1)-subunit is associated with absence epilepsy. Ann. Neurol. 2006, 59:983-987.
90. Marrosu F., Marrosu G., Rachel M.G., Biggio G. Paradoxical reactions elicited by diazepam in children with classic autism. Funct. Neurol. 1987, 2:355-361.
91. A-receptor subtypes really occur in the brain?. Trends Neurosci. 1996, 19:139-143.
92. 1 subtype. Nat. Neurosci. 2000, 3:587-592.
93. Medina-Kauwe L.K., Tobin A.J., De Meirleir L., Jaeken J., Jakobs C., Nyhan W.L., Gibson K.M. 4-Aminobutyrate aminotransferase (GABA-transaminase) deficiency. J. Inherit. Metab. Dis. 1999, 22:414-427.
94. Medrihan L., Tantalaki E., Aramuni G., Sargsyan V., Dudanova I., Missler M., Zhang W. Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. J. Neurophysiol. 2008, 99:112-121.
95. Miyashiro K.Y., Beckel-Mitchener A., Purk T.P., Becker K.G., Barret T., Liu L., Carbonetto S., Weiler I.J., Greenough W.T., Eberwine J. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 2003, 37:417-431.
96. Mody I., Pearce R.A. Diversity of inhibitory neurotransmission through GABA(A) receptors. Trends Neurosci. 2004, 27:569-575.
97. Monaghan E.P., Navalta L.A., Shum L., Ashbrook D.W., Lee D.A. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 1997, 38:1026-1031.
98. Musumeci S.A., Hagerman R.J., Ferri R., Bosco P., Dalla Bernardina B., Tassinari C.A., De Sarro G.B., Elia M. Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 1999, 40:1092-1099.
99. Neul J.L., Kaufmann W.E., Glaze D.G., Christodoulou J., Clarke A.J., Bahi-Buisson N., Leonard H., Bailey M.E., Schanen N.C., Zappella M., et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol. 2010, 68:944-950. RettSearch Consortium.
100. Nohria V., Giller E. Ganaxolone. Neurotherapeutics 2007, 4:102-105.
101. O'Roak B.J., Vives L., Girirajan S., Karakoc E., Krumm N., Coe B.P., Levy R., Ko A., Lee C., Smith J.D., et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 2012, 485:246-250.
102. Oakley J.C., Cho A.R., Cheah C.S., Scheuer T., Catterall W.A. Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome. J. Pharmacol. Exp. Ther. 2013, 345:215-224.
103. Ogiwara I., Miyamoto H., Morita N., Atapour N., Mazaki E., Inoue I., Takeuchi T., Itohara S., Yanagawa Y., Obata K., et al. Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J. Neurosci. 2007, 27:5903-5914.
104. Olmos-Serrano J.L., Corbin J.G., Burns M.P. The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome. Dev. Neurosci. 2011, 33:395-403.
105. Olsen R.W., Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev. 2008, 60:243-260.
106. Omrani A., van der Vaart T., Mientjes E., van Woerden G.M., Hojjati M.R., Li K.W., Gutmann D.H., Levelt C.N., Smit A.B., Silva A.J., et al. HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. Mol. Psychiatry 2015, Published online April 28, 2015. 10.1038/mp.2015.48.
107. Paluszkiewicz S.M., Martin B.S., Huntsman M.M. Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev. Neurosci. 2011, 33:349-364.
108. Pearl P.L., Gibson K.M., Quezado Z., Dustin I., Taylor J., Trzcinski S., Schreiber J., Forester K., Reeves-Tyer P., Liew C., et al. Decreased GABA-A binding on FMZ-PET in succinic semialdehyde dehydrogenase deficiency. Neurology 2009, 73:423-429.
109. Perrin S. Preclinical research: Make mouse studies work. Nature 2014, 507:423-425.
110. Perry T.L., Dunn H.G., Ho H.H., Crichton J.U. Cerebrospinal fluid values for monoamine metabolites, gamma-aminobutyric acid, and other amino compounds in Rett syndrome. J. Pediatr. 1988, 112:234-238.
111. Pieribone V.A., Tsai J., Soufflet C., Rey E., Shaw K., Giller E., Dulac O. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia 2007, 48:1870-1874.
112. Prasad D.K., Shaheen U., Satyanarayana U., Prabha T.S., Jyothy A., Munshi A. Association of GABRA6 1519 T>C (rs3219151) and Synapsin II (rs37733634) gene polymorphisms with the development of idiopathic generalized epilepsy. Epilepsy Res. 2014, 108:1267-1273.
113. Puskarjov M., Seja P., Heron S.E., Williams T.C., Ahmad F., Iona X., Oliver K.L., Grinton B.E., Vutskits L., Scheffer I.E., et al. A variant of KCC2 from patients with febrile seizures impairs neuronal Cl- extrusion and dendritic spine formation. EMBO Rep. 2014, 15:723-729.
114. Quilichini P.P., Chiron C., Ben-Ari Y., Gozlan H. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia 2006, 47:704-716.
115. Ramamoorthi K., Lin Y. The contribution of GABAergic dysfunction to neurodevelopmental disorders. Trends Mol. Med. 2011, 17:452-462.
116. Reis J., Cohen L.G., Pearl P.L., Fritsch B., Jung N.H., Dustin I., Theodore W.H. GABAB-ergic motor cortex dysfunction in SSADH deficiency. Neurology 2012, 79:47-54.
117. Rowley N.M., Madsen K.K., Schousboe A., Steve White H. Glutamate and GABA synthesis, release, transport and metabolism as targets for seizure control. Neurochem. Int. 2012, 61:546-558.
118. Rubenstein J.L., Merzenich M.M. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003, 2:255-267.
119. Rudolph U., Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discov. 2011, 10:685-697.
120. Rudolph U., Möhler H. GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu. Rev. Pharmacol. Toxicol. 2014, 54:483-507.
121. Rudolph U., Crestani F., Benke D., Brünig I., Benson J.A., Fritschy J.M., Martin J.R., Bluethmann H., Möhler H. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999, 401:796-800.
122. Sieghart W., Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr. Top. Med. Chem. 2002, 2:795-816.
123. Simon D.B., Karet F.E., Hamdan J.M., DiPietro A., Sanjad S.A., Lifton R.P. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat. Genet. 1996, 13:183-188.
124. Srivastava S., Cohen J., Pevsner J., Aradhya S., McKnight D., Butler E., Johnston M., Fatemi A. A novel variant in GABRB2 associated with intellectual disability and epilepsy. Am. J. Med. Genet. A. 2014, 164A:2914-2921.
125. Suhl J.A., Chopra P., Anderson B.R., Bassell G.J., Warren S.T. Analysis of FMRP mRNA target datasets reveals highly associated mRNAs mediated by G-quadruplex structures formed via clustered WGGA sequences. Hum. Mol. Genet. 2014, 23:5479-5491.
126. Tanaka M., Olsen R.W., Medina M.T., Schwartz E., Alonso M.E., Duron R.M., Castro-Ortega R., Martinez-Juarez I.E., Pascual-Castroviejo I., Machado-Salas J., et al. Hyperglycosylation and reduced GABA currents of mutated GABRB3 polypeptide in remitting childhood absence epilepsy. Am. J. Hum. Genet. 2008, 82:1249-1261.
127. Tomassy G.S., Morello N., Calcagno E., Giustetto M. Developmental abnormalities of cortical interneurons precede symptoms onset in a mouse model of Rett syndrome. J. Neurochem. 2014, 131:115-127.
128. Tsang S.Y., Zhong S., Mei L., Chen J., Ng S.K., Pun F.W., Zhao C., Jing B., Chark R., Guo J., et al. Social cognitive role of schizophrenia candidate gene GABRB2. PLoS One 2013, 8:e62322.
129. Tseng W.C., Jenkins P.M., Tanaka M., Mooney R., Bennett V. Giant ankyrin-G stabilizes somatodendritic GABAergic synapses through opposing endocytosis of GABAA receptors. Proc. Natl. Acad. Sci. USA 2015, 112:1214-1219.
130. Tyzio R., Nardou R., Ferrari D.C., Tsintsadze T., Shahrokhi A., Eftekhari S., Khalilov I., Tsintsadze V., Brouchoud C., Chazal G., et al. Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. Science 2014, 343:675-679.
131. van Bokhoven H. Genetic and epigenetic networks in intellectual disabilities. Annu. Rev. Genet. 2011, 45:81-104.
132. Verkerk A.J.M.H., Pieretti M., Sutcliffe J.S., Fu Y.-H., Kuhl D.P.A., Pizzuti A., Reiner O., Richards S., Victoria M.F., Zhang F.P., et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991, 65:905-914.
133. Violante I.R., Ribeiro M.J., Edden R.A., Guimarães P., Bernardino I., Rebola J., Cunha G., Silva E., Castelo-Branco M. GABA deficit in the visual cortex of patients with neurofibromatosis type 1: genotype-phenotype correlations and functional impact. Brain 2013, 136:918-925.
134. Voineagu I., Wang X., Johnston P., Lowe J.K., Tian Y., Horvath S., Mill J., Cantor R.M., Blencowe B.J., Geschwind D.H. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2011, 474:380-384.
135. Voituron N., Hilaire G. The benzodiazepine Midazolam mitigates the breathing defects of Mecp2-deficient mice. Respir. Physiol. Neurobiol. 2011, 177:56-60.
136. Wafford K.A., Ebert B. Gaboxadol-a new awakening in sleep. Curr. Opin. Pharmacol. 2006, 6:30-36.
137. Wallace R.H., Marini C., Petrou S., Harkin L.A., Bowser D.N., Panchal R.G., Williams D.A., Sutherland G.R., Mulley J.C., Scheffer I.E., Berkovic S.F. Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures. Nat. Genet. 2001, 28:49-52.
138. Warrier V., Baron-Cohen S., Chakrabarti B. Genetic variation in GABRB3 is associated with Asperger syndrome and multiple endophenotypes relevant to autism. Mol. Autism 2013, 4:48.
139. Yamashita Y., Matsuishi T., Ishibashi M., Kimura A., Onishi Y., Yonekura Y., Kato H. Decrease in benzodiazepine receptor binding in the brains of adult patients with Rett syndrome. J. Neurol. Sci. 1998, 154:146-150.
140. Yu F.H., Mantegazza M., Westenbroek R.E., Robbins C.A., Kalume F., Burton K.A., Spain W.J., McKnight G.S., Scheuer T., Catterall W.A. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat. Neurosci. 2006, 9:1142-1149.
141. Zhang L., He J., Jugloff D.G., Eubanks J.H. The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability. Hippocampus 2008, 18:294-309.
142. Zhang Z.W., Zak J.D., Liu H. MeCP2 is required for normal development of GABAergic circuits in the thalamus. J. Neurophysiol. 2010, 103:2470-2481.